pharmaphorum

SEPTEMBER 11, 2020

Prior to the $63 billion takeover by AbbVie, Allergan’s biggest product was botulinum toxin product Botox, best known as a wrinkle and migraine treatment, and that headed a sizeable medical aesthetics portfolio at the company which also included dermal filler products like Juvederm.

Botox 119

Botox Filler Production Marketing 119

Roots Analysis

JANUARY 3, 2024

Afterwards, in 2003, the FDA approved Hyaluronic Acid Fillers (HA dermal fillers), bringing the much-anticipated innovation to all types of face and non-face augmentation products. Moreover, at present, women dominate the medical aesthetics industry with over 90% market share.

Filler 40

Filler Cosmetics Production Dermatology 40

Roots Analysis

JANUARY 29, 2024

It is interesting to note that medical aesthetics companies are continuously enhancing their product portfolio to provide solutions based on the needs of the end user. The medical aesthetics companies are offering advanced products and devices to perform these procedures with better results and minimal downtime.

Filler 40

Filler Cosmetics Botox Marketing 40